Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessAnheuser-Busch InBev’s Price Target Cut at Morgan Stanley

Anheuser-Busch InBev’s Price Target Cut at Morgan Stanley

Add to Favorite
Added to Favorite


Morgan Stanley analysts adjusted their price target for Anheuser-Busch InBev (NYSE:BUD) to $68.50 from $69.00, while still recommending an Overweight rating. Morgan Stanley’s update incorporates the latest market data and currency valuations, noting that operational forecasts globally are nearly unchanged, with a slight increase in expected volumes for fiscal year 2024.
Adjustments were also made to reflect the impact of hyperinflation on pricing rather than revenue, although this doesn’t alter the fundamental forecasts. An increase in non-interest financial expenses for 2024 by $200 million has been included to account for the effects of Naira devaluation. Consequently, the EPS forecast for 2024 has decreased by 1%, while the forecast for 2025 has increased by 1%, leading to the revised price target.

Subscribe to get Latest News Updates

Latest News

You may like more
more

Lifecore Biomedical, Inc. (NASDAQ: LFCR) Quarterly Earnings Preview

Earnings per Share (EPS) loss is anticipated to be...

Evolv Technologies Holdings, Inc. (NASDAQ:EVLV) Faces Financial Challenges

Earnings per Share (EPS) of -$0.07 missed the estimated...

Arthur J. Gallagher & Co. (NYSE: AJG) Insider Purchase and Stock Performance

Gallagher Patrick Murphy, COO of Arthur J. Gallagher &...